| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of General Internal Medicine, Ambulatory Treatment, and Emergency Care (H.-L.Y., S.-C.J.Y.), Experimental Therapeutics (J.-X.P.), and Endocrine Neoplasia and Hormonal Disorders (L.S., S.-C.J.Y.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Address all correspondence and requests for reprints to: S. Jim Yeung, M.D., Ph.D., Assistant Professor, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 437, Houston, Texas 77030. E-mail: syeung{at}notes.mdacc.tmc.edu.
Our previous studies demonstrated that manumycin (a farnesyltransferase inhibitor) enhanced the antineoplastic activity and induction of apoptosis when combined with paclitaxel against anaplastic thyroid cancer cells. We found that manumycin induces endogenous expression of p21 Waf-1 in anaplastic thyroid cancer cells. Manumycin increased the activity of the p21promoter, the level of p21mRNA, and the amount of p21 protein. We hypothesized that p21 had a proapoptotic effect in cells treated with manumycin, or paclitaxel, or both agents. By measuring viability and caspase-3 activity, we found that stably transfected KAT-4 cells with p21 cDNA under the control of a metallothionein promoter were more sensitive to manumycin alone, paclitaxel alone, and manumycin plus paclitaxel when p21was induced. The increased sensitivity of the cells with induced p21 was associated with an increase in caspase-3 activity (i.e. apoptosis). We also found that cells with both p21 alleles deleted were less sensitive to manumycin plus paclitaxel than its wild-type parent cells. Expression of p21 per se did not induce apoptosis but enhanced the cytotoxic effects of manumycin and paclitaxel. These findings suggested that p21 might be required to maintain cell sensitivity to the cytotoxic effects of manumycin and paclitaxel.
This research was supported by a grant to S.-C.J.Y. from the American Cancer Society (RPG-99-154-01-CDD). H.-L.Y. is a visiting scientist from Zhongshan Medical College, Sun Yat-Sen University, Guangzhou, China.
H.-L.Y. and J.-X.P. contributed equally to this work.
Abbreviations: ATC, Anaplastic thyroid cancer; DMSO, dimethylsulfoxide; FTI, farnesyltransferase inhibitor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium.
This article has been cited by other articles:
![]() |
R. Aneja, A. M. Ghaleb, J. Zhou, V. W. Yang, and H. C. Joshi p53 and p21 Determine the Sensitivity of Noscapine-Induced Apoptosis in Colon Cancer Cells Cancer Res., April 15, 2007; 67(8): 3862 - 3870. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells Cancer Res., May 1, 2005; 65(9): 3671 - 3681. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Geller, K. Szekely-Szucs, I. Petak, B. Doyle, and J. A. Houghton P21Cip1 Is a Critical Mediator of the Cytotoxic Action of Thymidylate Synthase Inhibitors in Colorectal Carcinoma Cells Cancer Res., September 1, 2004; 64(17): 6296 - 6303. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhang, H. Wang, M. Li, S. Agrawal, X. Chen, and R. Zhang MDM2 Is a Negative Regulator of p21WAF1/CIP1, Independent of p53 J. Biol. Chem., April 16, 2004; 279(16): 16000 - 16006. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |